In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Catalent raises $650mm in preferred stock financing to fund Paragon acquisition

Executive Summary

Concurrent with and conditional upon its $1.2bn acquisition of US biologics CDMO Paragon Bioservices, Catalent Inc. entered a definitive agreement to issue up to $1bn of a new series of convertible preferred stock to funds affiliated with PE firm Leonard Green & Partners (LGP). LGP will pay $1k apiece to purchase up to 1mm Series A preferred shares, of which Catalent will issue $650mm. Separately, the company also brought in some money through a term loan under its existing senior secured credit facilities with JPMorgan Chase. Besides funding the acquisition, Catalent will use any remaining proceeds from these transactions to pay a portion of capital expansion project costs at Paragon’s Baltimore, MD gene therapy headquarters. An LGP partner will join the Catalent board.
Deal Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Services
  • Pharmaceuticals
    • OTC, Consumer
    • Drug Delivery
      • Controlled Release
      • Macromolecule
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
    • Synthesis Technologies, Production Processes
Deal Status
  • Final
Deal Type
  • Financing
    • Other
    • Private Placement

Related Companies